Polyplastics to showcase wearable insulin delivery device at K Show
The V-Go Wearable Insulin Delivery system, which features an injection moulded precision metering device made of Polyplastics’ TOPAS cyclic olefin copolymer (COC), will be featured at the upcoming K 2022 exhibition, which runs Oct. 19-26 in Düsseldorf, Germany.
The injection moulded metering device made of TOPAS COC delivers drug compatibility and dimensional stability in this product for daily diabetes treatment.
V-Go, a product offering from MannKind Corporation, is a once-daily, wearable, insulin delivery device that helps provide blood sugar control for everyday lifestyles. Designed to be patient-friendly, V-Go is worn like a patch and eliminates the need for taking multiple daily shots. The design is simple and manually controlled with the push of a button for a bolus dose, so it works just like an injection.
A critical component of V-Go’s insulin delivery product is the precision metering device made of TOPAS COC. After thorough research and evaluation, the material was selected over competitive thermoplastics due to its purity, drug compatibility, biocompatibility, and dimensional stability, according to Jeffrey Zajac, executive director, V-Go Device manufacturing. TOPAS COC can also be moulded with zero draft.
“TOPAS COC fills an important role in the metering device of the V-Go insulin delivery product,” said Zajac. “We find it to be highly stable in contact with the drug and it has great optical clarity; moreover, it offers good injection moulding characteristics with excellent dimensional stability and minimal shrinkage.”
Unlike other engineering thermoplastics or glass, TOPAS COC offers a non-ionic, minimally reactive surface. This non-polar substrate does not promote adsorption, denaturation, aggregation, or precipitation. “Glass-clear TOPAS resin has very low leachables and extractables compared to glass and other medical grade polymers for drug delivery and thus preserves long-term drug purity and enables better quality at high yields,” said Barbara Canale, healthcare market development manager for Polyplastics.